ArticleJournal of inflammation research2025
Catalpol Alleviates HFpEF via Inhibition of the S100A8-RAGE-NOX4 Inflammatory Axis in Murine Hearts.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to elucidate the therapeutic effects of catalpol (CAT) on heart failure with preserved ejection fraction (HFpEF) and explore its underlying mechanisms. Methods: An HFpEF mouse model was established by combining a high-fat diet with N^ω^-nitro-L-arginine methyl ester administration, followed by CAT treatment for four weeks. Cardiac function was assessed by echocardiography, while histopathological changes were evaluated using hematoxylin-eosin and Masson's trichrome staining. Network pharmacology and transcriptomic analyses were integrated to identify the core targets and signaling pathways of CAT in HFpEF. In vitro, H9C2 were stimulated with angiotensin II (Ang II), followed by CAT treatment, with recombinant rat S100A8 used to specifically activate the TLR4/RAGE pathway. Western blotting (WB) and quantitative real-time PCR were performed to validate the predicted signaling mechanisms both in vivo and in vitro. Results: In vivo, CAT markedly improved multiple pathological and functional abnormalities in HFpEF mice, including obesity, glucose intolerance, hypertension, diastolic dysfunction, myocardial inflammation, and fibrosis. Integrated network pharmacology and transcriptomic analyses consistently identified the RAGE signaling pathway as the key pathway of CAT. Molecular docking revealed strong binding affinities between CAT and S100A8, RAGE, NOX4, ERK1, and MMP2. WB results further demonstrated that CAT significantly downregulated the S100A8/RAGE/NOX4 axis and its downstream effector MMP2 in cardiac tissue. In vitro, CAT alleviated Ang II-induced cardiomyocyte hypertrophy, reduced the expression of inflammatory cytokines (TNF-α, IL-1β, IL-6) and the heart failure marker ANP, and inhibited S100A8, RAGE, and NOX4 protein levels. Notably, recombinant S100A8 activation weakened the protective effects of CAT. Conclusion: CAT exerts cardioprotective effects against HFpEF by suppressing myocardial inflammation and fibrosis through modulation of the S100A8/RAGE/NOX4 signaling axis and its downstream effectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.